Abstract:Introduction: Non-small cell lung cancer (NSCLC) with co-occurring loss-of-function (LOF) mutations in serine/threonine kinase 11 (STK11) and Kelch-like ECH-associated protein1 (KEAP1) (SK) are notably aggressive and unresponsive to chemo and immunotherapy, in current care standards. Novel therapeutic strategies are in demand to improve the outcomes for SK co-mutant NSCLC patients. We reported earlier that SK LOF mutations enhance cell proliferation and tumor growth in xenograft lung cancer models. We also found the ferroptosis evasion genes are enriched, and targeting ferroptosis regulators is a therapeutic opportunity in SK co-mutant NSCLC. Methods: We used CRISPR/Cas9 gene editing to create stable knockouts of STK11 (SKO), KEAP1 (KKO) or both (DKO), non-targeting control (NTC) in two NSCLC lines. We performed an in vitro druggable genome library CRISPR screening in the same NSCLC lines. We performed kinase profiling and RNA-seq in the cell lines to depict the transcriptomic and proteomic landscape, followed by western blotting and qRT-PCR validation. We also performed BODIPY/C11 assay and lipidomics to explore the ferroptosis and metabolic landscape of SK co-mutant NSCLC models. Results: Stearoyl CoA desaturase-1 (SCD1) was the top CRISPR screen hit, a critical modulator of fatty acid metabolism and ferroptosis evasion. SCD1 expression is significantly higher in NSCLC tissue than adjacent normal tissue (p<0.0001), and high SCD1 expression correlates with poorer prognosis in patients with NSCLC (p=0.027). GSEA from the bulk RNA sequencing in SK co-mutant cells pre-and post-SCD1 inhibitor treatment showed SCD1 inhibition leads to upregulation of the glutathione and glutamic acid pathways compared to NTC cells. Moreover, SK co-mutant cells have a significantly higher expression of SLC7A11, enabling cystine uptake and subsequent conversion to cysteine, essential for maintaining redox balance and cell survival. Hence, SK co-mutant cells are more resistant to cysteine depletion than NTC cells. SCD1 inhibition causes a decrease in SLC7A11 expression exclusively in DKO cells. Eventually, SCD1 inhibition leads to global metabolomic changes in SK co-mutant cells, including key pathways involved in lipid and glucose metabolism. Finally, genetic and pharmacological inhibition of SCD1 prevents tumor growth and sensitizes DKO cells to ferroptosis inducers like erastin. Conclusions: Our findings highlight the importance of the SCD1-SLC7A11 axis in regulating ferroptosis in SK co-mutant models. Current data impact our understanding of ferroptosis in NSCLC and its ability to target SCD1 or ferroptosis in cancer treatment. Compounds such as inhibitors of SLC7A11 (Erastin/IKE) are safe to use with acceptable toxicity and established doses. Hence, our study will facilitate the translation of ferroptosis inducers or SCD1 inhibitors in clinical trials. Citation Format: Utsav Sen, Charles Coleman, Dan Hasson, Triparna Sen. SCD1 upregulation due to STK11/KEAP1 loss upregulates SLC7A11 and causes deregulation of fatty acid metabolism leading to ferroptosis evasion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 641.

Htbk1-C.978t>a Mutation Promotes the Ferroptosis in NSC-34 Cells Via Mediation of KEAP1/NRF2/p62 Signaling.

L-3-n-Butylphthalide Protects HSPB8 K141N Mutation-Induced Oxidative Stress by Modulating the Mitochondrial Apoptotic and Nrf2 Pathways

ALS-Associated E478G Mutation in Human OPTN (optineurin) Promotes Inflammation and Induces Neuronal Cell Death

LKB1-AMPK Axis Negatively Regulates Ferroptosis by Inhibiting Fatty Acid Synthesis

Study on Aggregate Formation Mechanism of HSPB8 Gene Mutation Resulting in CMT2L

ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway

Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis

A TBK1 variant causes autophagolysosomal and motoneuron pathology without neuroinflammation in mice

Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function

TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS

RABGGTB plays a critical role in ALS pathogenesis

Abstract 641: SCD1 upregulation due to STK11/KEAP1 loss upregulates SLC7A11 and causes deregulation of fatty acid metabolism leading to ferroptosis evasion

Pathogenic mutation in the ALS/FTD gene, CCNF, causes elevated Lys48-linked ubiquitylation and defective autophagy

PRMT6-mediated ADMA promotes p62 phase separation to form a negative feedback loop in ferroptosis

Increased Vulnerability to Ferroptosis in FUS-ALS

Inhibition of PKA/CREB1 Pathway Confers Sensitivity to Ferroptosis in Non-Small Cell Lung Cancer

Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells

CKS2 induces autophagy-mediated glutathione metabolic reprogramming to facilitate ferroptosis resistance in colon cancer

Activation of the Keap1/Nrf2 pathway suppresses mitochondrial dysfunction, oxidative stress, and motor phenotypes in C9orf72 ALS/FTD models

Oncogenic RTKs sensitize cancer cells to ferroptosis via c-Myc mediated upregulation of ACSL4

AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc- Activity